The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
0702001 Informal Interpretation
0702002 Informal Interpretation
0701026 Informal Interpretation
0701022 Informal Interpretation
0701017 Informal Interpretation
0701019 Informal Interpretation
0701016 Informal Interpretation
Johnson & Johnson and Pfizer Inc., In the Matter of
The consent order settles charges that Johnson & Johnson’s (J&J) proposed $16.6 billion acquisition of Pfizer Inc.’s (Pfizer) Consumer Healthcare business would likely reduce competition in the U.S. markets for over-the-counter (OTC) H-2 blockers used to prevent and relieve heartburn, OTC hydrocortisone anti-itch products, OTC night-time sleep aids, and OTC diaper rash treatments. In settling the Commission’s charges, the companies have agreed to sell Pfizer’s Zantac H-2 blocker business to Boehringer Ingelheim Pharmaceuticals Inc. (Boehringer), and Pfizer’s Cortizone hydrocortisone anti-itch business, Pfizer’s Unisom night-time sleep aid business, and J&J’s Balmex diaper rash treatment business to Chattem, Inc.